HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed price. Currency in GBp
1,174.00
+4.00 (+0.34%)
As of 10:13AM BST. Market open.
Stock chart is not supported by your current browser
Previous close1,170.00
Open1,175.00
Bid1,174.00 x 16300
Ask1,175.00 x 34600
Day's range1,174.00 - 1,189.00
52-week range1,101.00 - 2,346.00
Volume62,148
Avg. volume881,326
Market cap2.82B
Beta0.12
PE ratio (TTM)17.01
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & Yield0.22 (1.44%)
Ex-dividend date2017-08-24
1y target estN/A
  • Fool.co.uk6 days ago

    2 growth stocks for the long run

    These two stocks could perform well in future years.

  • Fool.co.uk27 days ago

    2 turnaround stocks that could make you rich

    Bilaal Mohamed picks out two battered pharmaceutical stocks that could turn out to be excellent recovery plays.

  • Fool.co.uk2 months ago

    There could be hidden value in these FTSE 250 stocks

    G A Chester discusses his two top-value picks from the FTSE 250 (INDEXFTSE:MCX).

  • Fool.co.uk2 months ago

    Why this battered pharma stock could be a top turnaround buy

    Roland Head selects his turnaround pick from two of this year's biggest pharma fallers.

  • Reuters - UK Focus2 months ago

    BUZZ-Hikma: More price cuts on visibility issues

    ** Hikma Pharmaceuticals attempts bounce after steep losses since last week's half-year report, up as much as 3.9 pct, but these now almost erased ** Morgan Stanley cuts TP to 1350p from 1600p, Peel Hunt ...

  • Reuters - UK Focus2 months ago

    Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) 's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday. West-Ward Pharmaceuticals, the U.S. division of London-listed Hikma, increased the prices at the start of August by between 75 percent and 430 percent, for a mean of 237 percent, according to figures seen by the Financial Times. Among the six drugs, West-Ward is either the only U.S. supplier or one of two manufacturers.

  • Reuters - UK Focus2 months ago

    Fed-fuelled banking stumble cuts short FTSE winning streak

    Banks wilting on the prospect of slower U.S. rate hikes dented Britain's major share index on Thursday, and Kingfisher also weighed after a weaker quarterly sales performance. The FTSE 100 fell 0.6 percent, ...

  • Reuters - UK Focus2 months ago

    Drugmaker Hikma trims sales forecasts, shares fall

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low. The company had already cut its full-year guidance in May to the range of $2 billion-$2.1 billion at constant currency from $2.2 billion. "Price erosion by the entire generics industry has been significant," Brian Hoffmann, president of the company's U.S. generics business told Reuters.

  • Reuters - UK Focus2 months ago

    Drugmaker Hikma expects 2017 revenue at the lower end of guidance

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) said on Thursday it expected 2017 revenue at the lower end of its guidance, after increased competition in the generics business hit prices and volumes. The Jordan-based company, which makes and markets branded and non-branded generic and injectable drugs, said it now expected 2017 revenue to be about $2 billion, at the lower end of its previous forecast of $2 billion-$2.1 billion. In May, London-listed Hikma cut full-year guidance for the first time to the range of $2 billion-$2.1 billion at constant currency, down from $2.2 billion.

  • Reuters - UK Focus5 months ago

    FTSE climbs for fourth straight week, shrugging off Trump slump

    The FTSE 100 was up nearly 0.5 percent on the day, bringing it into positive territory for the week after its performance was dented by worries over turmoil in U.S. President Donald Trump's administration that sent stocks tumbling across the globe. Investors looked through the political uncertainty to a better earnings season and improved UK retail sales data which pointed to a brighter outlook for consumer-facing stocks.

  • Reuters - UK Focus5 months ago

    Britain's FTSE recovers, set for fourth straight week of gains

    Britain's major share index recovered on Friday after a pullback in the previous session, marching towards its fourth straight week of gains as investors focused on underlying earnings growth and better ...

  • Reuters - UK Focus5 months ago

    European shares recover at end of worst week in 6 months

    European shares rose on Friday, timidly recovering from heavy losses suffered this week after political turmoil fuelled worries over U.S. President Donald Trump's stimulus plans, denting appetite for riskier ...

  • Reuters - UK Focus5 months ago

    FTSE 100 breaks 9-day winning streak as miners, British Land fall

    Britain's top share index snapped a nine-day gaining streak on Wednesday, turning lower as U.S. political developments weighed on European equity markets, with mining stocks and banks the biggest sectoral ...

  • Reuters - UK Focus5 months ago

    Miners, Lloyds help FTSE hover near record high

    Britain's top share index held close to a record high on Wednesday, helped by gains among miners and banking stock Lloyds, though a fall in British Land's stock weighed on housing-focused peers. The blue ...

  • Reuters - UK Focus5 months ago

    Record close for Britain's FTSE as AstraZeneca soars

    Britain's top share index set a record close on Friday, sealing its strongest week since December as pharmaceutical stock AstraZeneca rose on a positive drug trial and broker upgrades buoyed individual firms. The blue chip FTSE 100 index finished the week 0.5 percent higher at 7,435.39 points, a record close and flirting with its record intraday levels of mid-March. AstraZeneca jumped 9 percent after its key immunotherapy drug durvalumab was shown to reduce the risk of death from lung cancer in a trial.

  • Reuters - UK Focus5 months ago

    Britain's FTSE heads for third straight week of gains as AstraZeneca rises

    Britain's top share index rose on Friday, on track for its third successive week of gains as pharmaceutical stock AstraZeneca rose after a positive drug trial and broker upgrades buoyed individual firms. The blue chip FTSE 100 index was up 0.2 percent at 7,0402.40 points by 0854 GMT, hitting its highest level in seven weeks. AstraZeneca was the biggest gainer, jumping 4.5 percent after its key immunotherapy drug durvalumab was shown to reduce the risk of death from lung cancer in a trial.

  • Reuters - UK Focus5 months ago

    Spanish stocks lead European pull-back with worst day in 6 months

    European shares pulled back on Thursday with Spanish blue chips suffering their biggest one-day loss in six months, weighed down by losses among banks, while Italian lender UniCredit shone after solid ...

  • Reuters - UK Focus5 months ago

    GSK escapes Advair hit for now as second generic bid fails

    GlaxoSmithKline (Other OTC: GLAXF - news) is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) said on Thursday the Food and Drug Administration (FDA) had decided not to approve its version of the inhaled treatment for asthma and chronic lung disease at this time, due to "major" issues with the application. Hikma and its partner Vectura are in a race with Mylan to launch the first U.S. generic copy of Advair that can be substituted for the original product in pharmacies.

  • Reuters - UK Focus5 months ago

    European shares ease, Unicredit boosts Italian banks

    Italian banks shone in lacklustre European trading on Thursday after Unicredit's results indicated its turnaround was gathering pace. Europe's STOXX 600 slipped 0.1 percent, while the eurozone's broader ...

  • Reuters - UK Focus5 months ago

    BUZZ-Hikma: bottom of STOXX as generic Advair faces US delay, 2017 approval unlikely

    ** Drugmaker Hikma down 8 pct, bottom of Stoxx 600 , with its partner Vectura -9% ** Hikma says US regulators have decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair ...

  • Reuters - UK Focus5 months ago

    Mylan says disagrees with FDA over generic Advair delay

    Drugmaker Mylan Inc, which is trying to launch a generic form of GlaxoSmithKline's Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the standards ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes